The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

UCLA’s urology department was awarded $6 million from the California Department of Health Care Services to continue providing care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
In Brief

Roswell Park brings lung healthcare initiative to indigenous communities across North America

A three-year grant from Lilly to Roswell Park Comprehensive Cancer Center is bringing rich lung health resources to Indigenous workplaces located across North America. Collaborating with human resources specialists with Tribal Nations and communities covering many regions of the U.S. and Canada, Roswell Park’s Department of Indigenous Cancer Health team will provide lung cancer screening workflow resources, lung wellness education, and patient navigation services for thousands of eligible individuals.
Clinical Roundup

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account